Pneumonia - Bacterial
88
6
9
53
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
15 trials with published results (17%)
Research Maturity
53 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.5%
4 terminated out of 88 trials
93.0%
+6.5% vs benchmark
16%
14 trials in Phase 3/4
28%
15 of 53 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 53 completed trials
Clinical Trials (88)
MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)
Systematic Search for Primary Immunodeficiency in Adults With Infections
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE)
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Discharge Stewardship in Children's Hospitals
A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
Urine Pneumococcal Antigen Project
Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.
Urease Breath Test for Rapid Characterization of Pneumonia
Comparison Between the Progostic Value of the Procalcitonin and the Platelet/Total Leukocytic Count Ratio in Sepsis
Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia - ToolCAP
Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia
Antimicrobial Therapeutic Drug Monitoring During Lung Transplant Perioperative Phase